Company news
Hvivo Plc (LSE:HVO) news
Every Hvivo Plc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
HVIVO : H1 2026 Trading Update
July 23, 2026
Change of Auditor
July 13, 2026
Consultancy contract with Decoy Therapeutics
June 1, 2026
Grant of awards under Long Term Incentive Plan
May 29, 2026
£6m Influenza HCT contract signed
May 7, 2026
HCT contract signed with ILiAD Biotechnologies
April 22, 2026
Final Results 2025
April 15, 2026
hVIVO launches unified brand identity
April 14, 2026
Issue of Equity and Total Voting Rights
February 23, 2026
Trading Update
January 29, 2026
Notice of Trading Update
January 27, 2026
Appointment of Non-Executive Director
December 18, 2025
CEO & CFO Share Purchase
December 15, 2025
MSD to acquire Cidara
November 27, 2025
>£5 million CRS contracts signed
November 20, 2025
Positive data from novel human challenge models
November 11, 2025
Holding(s) in Company
November 6, 2025
Presentation at Jefferies Healthcare Conference
November 3, 2025
Interim results
September 23, 2025
Notice of Results
September 4, 2025
Appointment of Non-Executive Chair
September 1, 2025
Proposed appointment of Chair
July 29, 2025
H1 Trading update
July 22, 2025
Directorate Change
July 18, 2025
Positive results from client Phase 2b field study
June 30, 2025
Result of AGM
June 5, 2025
Director/PDMR Shareholding
June 2, 2025
Trading update
May 30, 2025
Appointment of Independent Non-Executive Director
May 29, 2025
Annual Report, Notice of AGM & Directorate Change
May 12, 2025
Exercise of Options
April 10, 2025
Final results
April 10, 2025
AIM Rule 17 and Schedule 2(g) Update
March 26, 2025
Acquisition of Cryostore for up to £3.2m
February 27, 2025
£2m hMPV characterisation study contract
February 17, 2025
Shionogi reports positive RSV trial results
February 5, 2025
RSV contract signed with Inhalon Biopharma
February 3, 2025
Acquisition: two Clinical Research Units from CRS
January 29, 2025
LOI signed for Phase 3 Whooping Cough trial
January 27, 2025
£3.2m hLAB project
January 21, 2025
hMPV challenge model update
January 13, 2025
COVID-19 study published in Nature Communications
December 12, 2024
£11.5m RSV contract and notice of trading update
December 10, 2024
Presentation at Jefferies London Healthcare Conf
November 5, 2024
Long Term Incentive Plan/ PDMR Notification
October 11, 2024
Positive results from RSV human challenge trial
October 7, 2024
Launch of full suite of hLAB standalone services
September 30, 2024
Notice of results
August 20, 2024
Euronext cancellation
August 5, 2024
Change of registered address
July 2, 2024